These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 15285797)

  • 21. Differential ability of a thiazolidinedione PPARgamma agonist to attenuate cytokine secretion in primary microglia and macrophage-like cells.
    Woster AP; Combs CK
    J Neurochem; 2007 Oct; 103(1):67-76. PubMed ID: 17573821
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Involvement of glucocorticoid receptor activation on anti-inflammatory effect induced by peroxisome proliferator-activated receptor γ agonist in mice.
    Yamamoto A; Kakuta H; Sugimoto Y
    Int Immunopharmacol; 2014 Sep; 22(1):204-8. PubMed ID: 24975659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of the PPARgamma activator pioglitazone on p38 MAP kinase and IkappaBalpha in the spinal cord of a transgenic mouse model of amyotrophic lateral sclerosis.
    Shibata N; Kawaguchi-Niida M; Yamamoto T; Toi S; Hirano A; Kobayashi M
    Neuropathology; 2008 Aug; 28(4):387-98. PubMed ID: 18312546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pro-inflammatory cytokines negatively regulate PPARγ mediated gene expression in both human and murine macrophages via multiple mechanisms.
    Nagy ZS; Czimmerer Z; Szanto A; Nagy L
    Immunobiology; 2013 Nov; 218(11):1336-44. PubMed ID: 23870825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Carnosic acid and carnosol, phenolic diterpene compounds of the labiate herbs rosemary and sage, are activators of the human peroxisome proliferator-activated receptor gamma.
    Rau O; Wurglics M; Paulke A; Zitzkowski J; Meindl N; Bock A; Dingermann T; Abdel-Tawab M; Schubert-Zsilavecz M
    Planta Med; 2006 Aug; 72(10):881-7. PubMed ID: 16858665
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
    Tjokroprawiro A
    Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis.
    Feinstein DL; Galea E; Gavrilyuk V; Brosnan CF; Whitacre CC; Dumitrescu-Ozimek L; Landreth GE; Pershadsingh HA; Weinberg G; Heneka MT
    Ann Neurol; 2002 Jun; 51(6):694-702. PubMed ID: 12112074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pro-inflammatory Macrophages suppress PPARγ activity in Adipocytes via S-nitrosylation.
    Yin R; Fang L; Li Y; Xue P; Li Y; Guan Y; Chang Y; Chen C; Wang N
    Free Radic Biol Med; 2015 Dec; 89():895-905. PubMed ID: 26475041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of PPARs in inflammation and immunity.
    Clark RB
    J Leukoc Biol; 2002 Mar; 71(3):388-400. PubMed ID: 11867676
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Full and partial peroxisome proliferation-activated receptor-γ agonists, but not δ agonist, rescue of dopaminergic neurons in the 6-OHDA parkinsonian model is associated with inhibition of microglial activation and MMP expression.
    Sadeghian M; Marinova-Mutafchieva L; Broom L; Davis JB; Virley D; Medhurst AD; Dexter DT
    J Neuroimmunol; 2012 May; 246(1-2):69-77. PubMed ID: 22498097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peroxisome proliferator-activated receptors and the vascular system: beyond their metabolic effects.
    Marchesi C; Schiffrin EL
    J Am Soc Hypertens; 2008; 2(4):227-38. PubMed ID: 20409905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FABP4 inhibition suppresses PPARγ activity and VLDL-induced foam cell formation in IL-4-polarized human macrophages.
    Boss M; Kemmerer M; Brüne B; Namgaladze D
    Atherosclerosis; 2015 Jun; 240(2):424-30. PubMed ID: 25897794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A PPARs cross-talk concertedly commits C6 glioma cells to oligodendrocytes and induces enzymes involved in myelin synthesis.
    Leisewitz AV; Urrutia CR; Martinez GR; Loyola G; Bronfman M
    J Cell Physiol; 2008 Nov; 217(2):367-76. PubMed ID: 18543250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of DSP-8658, a novel selective peroxisome proliferator-activated receptors a/γ modulator, on adipogenesis and glucose metabolism in diabetic obese mice.
    Goto T; Nakayama R; Yamanaka M; Takata M; Takazawa T; Watanabe K; Maruta K; Nagata R; Nagamine J; Tsuchida A; Kato H
    Exp Clin Endocrinol Diabetes; 2015 Sep; 123(8):492-9. PubMed ID: 26011171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PPARγ activation alters fatty acid composition in adipose triglyceride, in addition to proliferation of small adipocytes, in insulin resistant high-fat fed rats.
    Sato D; Oda K; Kusunoki M; Nishina A; Takahashi K; Feng Z; Tsutsumi K; Nakamura T
    Eur J Pharmacol; 2016 Feb; 773():71-7. PubMed ID: 26825545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of PPARγ in myeloid cells promotes lung cancer progression and metastasis.
    Nemenoff R
    Oncoimmunology; 2012 May; 1(3):403-404. PubMed ID: 22737631
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diabetes: Safer PPARγ-targeted drugs on the horizon?
    Crunkhorn S
    Nat Rev Drug Discov; 2011 Oct; 10(11):814. PubMed ID: 21997749
    [No Abstract]   [Full Text] [Related]  

  • 38. Ultrasound reduces inflammation by modulating M1/M2 polarization of microglia through STAT1/STAT6/PPARγ signaling pathways.
    Hsu CH; Pan YJ; Zheng YT; Lo RY; Yang FY
    CNS Neurosci Ther; 2023 Dec; 29(12):4113-4123. PubMed ID: 37401041
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Liu H; Zang C; Shang J; Zhang Z; Wang L; Yang H; Sheng C; Yuan F; Ju C; Li F; Yu Y; Yao X; Bao X; Zhang D
    Food Nutr Res; 2022; 66():. PubMed ID: 35950104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuropathophysiology of coronavirus disease 2019: neuroinflammation and blood brain barrier disruption are critical pathophysiological processes that contribute to the clinical symptoms of SARS-CoV-2 infection.
    Welcome MO; Mastorakis NE
    Inflammopharmacology; 2021 Aug; 29(4):939-963. PubMed ID: 33822324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.